VERCYTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERCYTE (VERCYTE).
VERCYTE (luspatercept) is a recombinant fusion protein that acts as a ligand trap for members of the transforming growth factor-beta (TGF-β) superfamily, including GDF11. It binds to these ligands, inhibiting Smad2/3 signaling, thereby promoting late-stage erythroid differentiation and maturation.
| Metabolism | VERCYTE is a recombinant fusion protein and is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic enzymes involved. |
| Excretion | Renal: 30-40% unchanged; biliary/fecal: 40-50% as metabolites; total clearance 0.5 L/h/kg. |
| Half-life | Terminal half-life 12-15 hours in healthy adults; prolonged to 24-36 hours in hepatic impairment. |
| Protein binding | 95% bound to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd 4-6 L/kg indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; IV: 100%. |
| Onset of Action | Oral: 1-2 hours; IV: 5-10 minutes. |
| Duration of Action | 8-12 hours based on target receptor occupancy; clinical effect may last 24 hours. |
150 mg orally once daily for 5 consecutive days, then 150 mg orally once daily every other day (on days 1, 3, 5) for a total cycle of 28 days. Administer on an empty stomach (1 hour before or 2 hours after meals).
| Dosage form | TABLET |
| Renal impairment | GFR ≥60 mL/min: no adjustment; GFR 30-59 mL/min: reduce dose to 100 mg daily; GFR <30 mL/min: not recommended (no data). |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 100 mg daily; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for pediatric use. Safety and efficacy not established in patients under 18 years. |
| Geriatric use | No specific dose adjustment recommended. Monitor renal function due to age-related decline; consider dose reduction if GFR <60 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VERCYTE (VERCYTE).
| Breastfeeding | No human data exist on the excretion of ribavirin in breast milk. Animal studies show ribavirin is excreted in milk. Because of the potential for adverse effects in nursing infants, breastfeeding is not recommended during therapy and for 6 months after the last dose. M/P ratio not determined. |
| Teratogenic Risk | VERCYTE (ribavirin) is contraindicated in pregnant women. It is teratogenic in all animal species tested and has a boxed warning for teratogenicity. First trimester exposure carries the highest risk, with potential for cranial, skeletal, and cardiovascular defects. Second and third trimester risks include growth restriction and central nervous system abnormalities. Effective contraception must be used during therapy and for 6 months after discontinuation in both female patients and male patients with female partners. |
■ FDA Black Box Warning
VERCYTE has a boxed warning for thromboembolic events (TEEs), including stroke, deep vein thrombosis, and pulmonary embolism. Increased risk in patients with beta-thalassemia and those with MDS. Monitor for signs and symptoms of TEEs and manage promptly.
| Serious Effects |
["Hypertension: uncontrolled hypertension (relative)","Pregnancy: can cause fetal harm (absolute)","History of thromboembolic events (relative)"]
| Precautions | ["Thromboembolic events: increased risk, especially in beta-thalassemia and MDS patients","Hypertension: monitor blood pressure regularly","May delay or prevent pregnancy in females of reproductive potential","Laboratory monitoring: hemoglobin levels should not exceed 11.5 g/dL to minimize risk of TEEs","Embryo-fetal toxicity: can cause fetal harm, advise effective contraception"] |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count (hemoglobin, hematocrit, white blood cell count, platelets) at baseline and weekly during therapy. Assess liver function tests (ALT, AST, bilirubin) and renal function (serum creatinine, BUN) monthly. Obtain pregnancy test immediately before initiation, monthly during therapy, and 6 months post-discontinuation. Monitor for hemolytic anemia (hemoglobin <10 g/dL). |
| Fertility Effects | Reversible inhibition of spermatogenesis has been observed in animal studies, with decreased sperm counts and motility. In humans, ribavirin may impair fertility in males; effects are reversible upon discontinuation. Female fertility effects are less well-characterized but may involve disrupted ovarian function. Avoid conception during therapy and for 6 months after treatment in both sexes. |